CBT profiles of cabozantinib approved for advanced renal cell carcinomas

Abstract

Cabozantinib (CABOMETYX, Exelixis, Inc.) was recently approved by the US Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. The approval was based on a randomized study in which patients with advanced renal cell carcinoma, who had received a prior anti-angiogenic… (More)
DOI: 10.1007/s10565-016-9349-6

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics